800 related articles for article (PubMed ID: 19405003)
21. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
[TBL] [Abstract][Full Text] [Related]
22. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.
Klotsche J; Raab A; Niewerth M; Sengler C; Ganser G; Kallinich T; Niehues T; Hufnagel M; Thon A; Hospach T; Horneff G; Minden K
Arthritis Rheumatol; 2016 Dec; 68(12):3023-3034. PubMed ID: 27332999
[TBL] [Abstract][Full Text] [Related]
23. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
[TBL] [Abstract][Full Text] [Related]
24. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis.
McErlane F; Beresford MW; Baildam EM; Chieng SE; Davidson JE; Foster HE; Gardner-Medwin J; Lunt M; Wedderburn LR; Thomson W; Hyrich KL;
Ann Rheum Dis; 2013 Dec; 72(12):1983-8. PubMed ID: 23256951
[TBL] [Abstract][Full Text] [Related]
25. Strong relationships between disease activity, foot-related impairments, activity limitations and participation restrictions in children with juvenile idiopathic arthritis.
Dekker M; Hoeksma AF; Dekker JH; van Rossum MA; Dolman KM; Beckerman H; Roorda LD
Clin Exp Rheumatol; 2010; 28(6):905-11. PubMed ID: 21122275
[TBL] [Abstract][Full Text] [Related]
26. Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis.
Viswanath V; Myles A; Dayal R; Aggarwal A
J Rheumatol; 2011 Nov; 38(11):2482-7. PubMed ID: 21885500
[TBL] [Abstract][Full Text] [Related]
27. What matters most for patients, parents, and clinicians in the course of juvenile idiopathic arthritis? A qualitative study.
Guzman J; Gómez-Ramírez O; Jurencak R; Shiff NJ; Berard RA; Duffy CM; Oen K; Petty RE; Benseler SM; Brant R; Tucker LB
J Rheumatol; 2014 Nov; 41(11):2260-9. PubMed ID: 25225279
[TBL] [Abstract][Full Text] [Related]
28. Facilitating patient-centered care: the development of illustrated multidimensional patient-reported outcome measures for children/adolescents with juvenile idiopathic arthritis.
El Miedany Y; El Gaafary M; Lotfy H; El Aroussy N; Mekkawy D; Nasef SI; Elderiny G; Farag Y; Hassan M
Clin Rheumatol; 2019 Aug; 38(8):2219-2226. PubMed ID: 30834997
[TBL] [Abstract][Full Text] [Related]
29. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Reiff A; Lovell DJ; Adelsberg JV; Kiss MH; Goodman S; Zavaler MF; Chen PY; Bolognese JA; Cavanaugh P; Reicin AS; Giannini EH
J Rheumatol; 2006 May; 33(5):985-95. PubMed ID: 16583464
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis.
Norambuena R X; Mallol J; Ríos M G; Quevedo R F; Quezada L A
Allergol Immunopathol (Madr); 2007; 35(2):52-6. PubMed ID: 17428400
[TBL] [Abstract][Full Text] [Related]
32. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
[TBL] [Abstract][Full Text] [Related]
33. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
34. Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index?
Saad-Magalhães C; Pistorio A; Ravelli A; Filocamo G; Viola S; Brik R; Mihaylova D; Cate RT; Andersson-Gare B; Ferriani V; Minden K; Hashkes P; Rygg M; Sauvain MJ; Venning H; Martini A; Ruperto N;
Ann Rheum Dis; 2010 Jan; 69(1):82-7. PubMed ID: 19221399
[TBL] [Abstract][Full Text] [Related]
35. Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease.
Palmisani E; Solari N; Magni-Manzoni S; Pistorio A; Labò E; Panigada S; Martini A; Ravelli A
Arthritis Rheum; 2006 Dec; 55(6):843-9. PubMed ID: 17139659
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
37. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
[TBL] [Abstract][Full Text] [Related]
38. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
Brunner HI; Quartier P; Alexeeva E; Constantin T; Koné-Paut I; Marzan K; Schneider R; Wulffraat NM; Chasnyk V; Tirosh I; Kallinich T; Kuemmerle-Deschner J; Wouters C; Lauwerys B; Nikishina I; Trachana M; Vougiouka O; Martini A; Lovell DJ; Levy J; Vritzali E; Ruperto N;
Arthritis Rheumatol; 2020 Dec; 72(12):2147-2158. PubMed ID: 32648697
[TBL] [Abstract][Full Text] [Related]
40. Weighting improves the information provided by joint counts on the severity of arthritis and its impact on patients' well-being in juvenile idiopathic arthritis.
Bandeira M; Falcone A; Pistorio A; Ruperto N; Magni-Manzoni S; Buoncompagni A; Sala E; Loy A; Martini A; Ravelli A
Rheumatology (Oxford); 2006 Mar; 45(3):343-7. PubMed ID: 16234273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
